By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: The Avestagenome Project and TIGS Sign Strategic Alliance to Advance Research in Rare Genetic Disorders
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Health

The Avestagenome Project and TIGS Sign Strategic Alliance to Advance Research in Rare Genetic Disorders

PRNW Agency
Last updated: 25/02/2025 2:34 AM
PRNW Agency
Share
5 Min Read
The Avestagenome Project and TIGS Sign Strategic Alliance to Advance Research in Rare Genetic Disorders
SHARE
The Avestagenome Project and TIGS Sign Strategic Alliance to Advance Research in Rare Genetic Disorders

BENGALURU, India, Feb. 24, 2025 /PRNewswire/ — The Avestagenome Project® International Pvt. Ltd. (AGENOME) & Avesthagen Limited, in partnership with the Tata Institute for Genetics and Society (TIGS), have signed a Strategic Alliance Agreement to advance research and development in rare genetic disorders, with a focus on the Zoroastrian Parsi community. This partnership aims to deepen our understanding and develop targeted solutions for conditions such as congenital deafness, muscular dystrophies, Parkinson’s disease, multiple sclerosis and other rare disorders requiring further investigation, ultimately contributing to the development of new products that benefit the global community.

The research partnership will leverage AGENOME’s extensive Biobank, which holds 4,700 blood samples from the Zoroastrian Parsi community, a valuable resource for studying genetic diseases. Of these, 350 samples have already been sequenced, marking a critical step toward uncovering genetic markers that contribute to rare disorders. This Biobank, combined with TIGS’ expertise in functional genomics and molecular biology, will help drive innovations in early diagnosis and therapeutic interventions. Additionally, AGENOME’s prior research partnership with the National Centre for Biological Sciences (NCBS) on neurological disorders such as Schizophrenia and Alzheimer’s disease has already laid a strong foundation in understanding complex genetic conditions. The current partnership with TIGS further strengthens this effort, bringing together cutting-edge research in multiple disease areas. By integrating insights from both partnerships, this initiative is poised to make significant contributions to the broader field of genetic research and disease management.

Advancing Research for Rare Genetic Disorders

This research partnership is poised to drive groundbreaking advancements in rare disease research, paving the way for innovative diagnostic and therapeutic solutions.

- Advertisement -

Key focus areas of this research partnership include:

  • Rare genetic disease diagnosis: Leveraging genome data to identify novel and relevant markers for developing diagnostic and screening assays (using CRISPR technologies) at a population scale.
  • Exploring mRNA therapeutics: Substituting enzyme replacement therapy (ERT) with the development of mRNA-based treatments where applicable.
  • In vivo gene therapy: Jointly assessing the potential for in vivo gene therapy for diseases relevant to the population based on genome data insights.
  • Profiling actionable pharmacogenomic markers: Identifying genetic variants that influence drug efficacy and safety, contributing to advancements in precision medicine.

Speaking on the research partnership, Dr. Villoo Morawala Patell, Founder & CMD of AGENOME and Avesthagen Limited, emphasized the significance of this partnership: “We are thrilled to embark on this groundbreaking research partnership between AGENOME and TIGS to decode the biology of rare genetic diseases. This alliance holds immense potential, not only for advancing scientific understanding but also for driving the creation of innovative, life-changing solutions that will benefit the communities affected worldwide.”

Dr. Rakesh Mishra, Director of TIGS, highlighted the potential impact of this alliance: “A significant amount of genome data from segregated communities, such as the Parsi community in India, with associated metadata offers the potential for fast and accurate diagnosis and novel treatments for difficult-to-diagnose diseases. Our partnership aims to bring advanced genome science benefits to society.”

Ensuring Impact and Accessibility

A key aspect of this initiative is the commitment to ensuring that the knowledge gained and therapies developed benefit those most affected. The insights gained from this research are expected to have far-reaching implications for other rare genetic disorders worldwide. A Joint Steering Committee, co-chaired by Dr. Patell and Dr. Mishra, will oversee the progress of the research, ensuring that scientific, ethical and commercialization strategies align with the broader goal of improving global health outcomes.

- Advertisement -

A Landmark Initiative in Genetic Research

This research partnership marks an important step in positioning India as a leader in rare disease research. The knowledge generated through this initiative will not only benefit the Zoroastrian Parsi community but could also be extended to other populations, paving the way for broader applications in precision medicine.

For media inquiries, please contact:
The Avestagenome Project® International Pvt. Ltd.:
Dr. Kayzad Soli Nilgiriwala
Vice President, Research & Development and Business Development
The Avestagenome Project® International Pvt. Ltd.
Mobile: +91 9920519393
E-mail: kayzadnilgiriwala@theavestagenomeproject.com

- Advertisement -

Tata Institute for Genetics and Society (TIGS):
E-mail: info@tigs.res.in

 

View original content:https://www.prnewswire.com/in/news-releases/the-avestagenome-project-and-tigs-sign-strategic-alliance-to-advance-research-in-rare-genetic-disorders-302383143.html

You Might Also Like

THE ROYAL CANADIAN MINT LAUNCHES ITS BIGGEST-EVER 99.99% PURE SILVER MAPLE LEAF COIN

Quantinuum Announces Generative Quantum AI Breakthrough with Massive Commercial Potential

Glenfarne Becomes Lead Developer for the Alaska LNG Project

Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), GPC Bio, and Eleszto Genetika Announce Strategic Unification

Candidature documents for the IOC presidential candidates now available

TAGGED:advanceagenomeagenomesalliancealreadyavestagenomeavesthagenbengalurubiobankcommunityconditionsdevelopmentdiseasedisordersfebfurthergeneticindia:internationalltdmultipleparsipartnershipprojectpvtrareResearchsamplessignstrategicthe avestagenometigsuncategorizedunderstandingwillzoroastrian

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Compass Health announces the Marc Healing Center as name of state-of-the-art regional facility for intensive behavioral health services Compass Health announces the Marc Healing Center as name of state-of-the-art regional facility for intensive behavioral health services
Next Article Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy Testing Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy Testing

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

Monarch Strikes Gold — A Win That Could Change How the World Sees Indian Brandy
Monarch Strikes Gold — A Win That Could Change How the World Sees Indian Brandy
Food 10/06/2025
Cisco Transforms Security for the Agentic AI Era, Further Fusing Security into the Network
Cisco Transforms Security for the Agentic AI Era, Further Fusing Security into the Network
Business 10/06/2025
Cisco Transforms Security for the Agentic AI Era, Further Fusing Security into the Network
Cisco Unveils Secure Network Architecture to Accelerate Workplace AI Transformation
Business 10/06/2025
Compass Mining Launches New Brand Identity, Marking a New Chapter in Its Growth Journey
Compass Mining Launches New Brand Identity, Marking a New Chapter in Its Growth Journey
Business 10/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?